BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opinion on Investigational Drugs 2014;23:561-71. [DOI: 10.1517/13543784.2014.892581] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Mcconachie SM, Wilhelm SM, Kale-pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2015;9:287-302. [DOI: 10.1586/17512433.2016.1129272] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
2 Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20:235-241. [PMID: 25944238 DOI: 10.1097/mot.0000000000000198] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
3 Yang S, Kao J. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:9-20. [DOI: 10.1586/17474124.2014.953930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504. [PMID: 25061308 DOI: 10.2147/tcrm.s66731] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Gentile I, Buonomo AR, Zappulo E, Borgia G. Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs 2015;24:239-51. [DOI: 10.1517/13543784.2015.982274] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
6 Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs. 2014;23:719-728. [PMID: 24666106 DOI: 10.1517/13543784.2014.902049] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
7 Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther. 2014;12:775-782. [PMID: 24840817 DOI: 10.1586/14787210.2014.920254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
8 Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12:763-73. [PMID: 24918116 DOI: 10.1586/14787210.2014.929497] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
9 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fatouh AM, Elshafeey AH, Abdelbary A. Liver targeting of ledipasvir via galactosylated chitosan-coated spanlastics: chemical synthesis, statistical optimization, in vitro, and pharmacokinetic evaluation. Drug Deliv Transl Res 2021. [PMID: 33948896 DOI: 10.1007/s13346-021-00993-8] [Reference Citation Analysis]
11 Ing Lorenzini K, Girardin F. Direct‐acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV‐infected patients. Liver Int 2019;40:32-44. [DOI: 10.1111/liv.14283] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health. 2014;6:605-611. [PMID: 24966696 DOI: 10.2147/ijwh.s51138] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
13 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
14 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
15 Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23:1211-1223. [PMID: 24848437 DOI: 10.1517/13543784.2014.921680] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
16 Gentile I, Buonomo AR, Zappulo E, Coppola N, Borgia G. GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12:1179-86. [PMID: 25096404 DOI: 10.1586/14787210.2014.945432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Gentile I, Borgia G. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. Evid Based Med 2014;19:223-4. [PMID: 25028605 DOI: 10.1136/ebmed-2014-110051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
18 Luo G, Xiang M, Krische MJ. Successive Nucleophilic and Electrophilic Allylation for the Catalytic Enantioselective Synthesis of 2,4-Disubstituted Pyrrolidines. Org Lett 2019;21:2493-7. [PMID: 30816719 DOI: 10.1021/acs.orglett.9b00508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kumari R, Nguyen MH. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother 2015;16:739-48. [PMID: 25676581 DOI: 10.1517/14656566.2015.1013938] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
20 Bourlière M, Adhoute X, Ansaldi C, Oules V, Benali S, Portal I, Castellani P, Halfon P. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Expert Rev Gastroenterol Hepatol 2015;9:1483-94. [PMID: 26595560 DOI: 10.1586/17474124.2015.1111757] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
21 Hassan ST, Berchová-Bímová K, Petráš J. Plumbagin, a Plant-Derived Compound, Exhibits Antifungal Combinatory Effect with Amphotericin B against Candida albicans Clinical Isolates and Anti-hepatitis C Virus Activity. Phytother Res 2016;30:1487-92. [PMID: 27215409 DOI: 10.1002/ptr.5650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
22 Patel S, Andres J, Qureshi K. An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function. Case Rep Med 2016;2016:3191089. [PMID: 27635145 DOI: 10.1155/2016/3191089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
23 Zimner-Rapuch S, Janus N, Deray G, Launay-Vacher V. New therapies for hepatitis C: considerations in patients with renal impairment. Drugs. 2014;74:1307-1313. [PMID: 25060981 DOI: 10.1007/s40265-014-0268-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Cannalire R, Barreca ML, Manfroni G, Cecchetti V. A Journey around the Medicinal Chemistry of Hepatitis C Virus Inhibitors Targeting NS4B: From Target to Preclinical Drug Candidates. J Med Chem 2016;59:16-41. [PMID: 26241789 DOI: 10.1021/acs.jmedchem.5b00825] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
26 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Fatouh AM, Elshafeey AH, Abdelbary A. Galactosylated Chitosan Coated Liposomes of Ledipasvir for Liver Targeting: Chemical Synthesis, Statistical Optimization, In-vitro and In-vivo evaluation. J Pharm Sci 2021;110:1148-59. [PMID: 33039437 DOI: 10.1016/j.xphs.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Flick AC, Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, O’donnell CJ. Synthetic approaches to the 2014 new drugs. Bioorganic & Medicinal Chemistry 2016;24:1937-80. [DOI: 10.1016/j.bmc.2016.03.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
29 Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
30 Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9:e94542. [PMID: 24728219 DOI: 10.1371/journal.pone.0094542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
31 Gentile I, Borgia G. A pill a day keeps HCV away. Lancet Infect Dis 2015;15:616-7. [PMID: 25863561 DOI: 10.1016/S1473-3099(15)70127-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
32 Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J Transl Int Med. 2017;5:8-17. [PMID: 28680834 DOI: 10.1515/jtim-2017-0007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 10.6] [Reference Citation Analysis]
33 Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Peña JM. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 2015;11:333-41. [PMID: 25553890 DOI: 10.1517/17425255.2015.998997] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
34 Jiang Z, Wang H, Li Y, Peng Z, Li Y, Li Z. Synthesis and antiviral activity of a series of novel N-phenylbenzamide and N-phenylacetophenone compounds as anti-HCV and anti-EV71 agents. Acta Pharm Sin B 2015;5:201-9. [PMID: 26579447 DOI: 10.1016/j.apsb.2015.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
35 Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs 2016;25:557-72. [DOI: 10.1517/13543784.2016.1161023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
36 Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015;24:1111-21. [PMID: 26156630 DOI: 10.1517/13543784.2015.1059820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
37 Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf 2015;14:1631-46. [PMID: 26329454 DOI: 10.1517/14740338.2015.1084287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
38 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
39 Campa A, Martinez SS, Sherman KE, Greer JP, Li Y, Garcia S, Stewart T, Ibrahimou B, Williams OD, Baum MK. Cocaine Use and Liver Disease are Associated with All-Cause Mortality in the Miami Adult Studies in HIV (MASH) Cohort. J Drug Abuse 2016;2:27. [PMID: 28540368 DOI: 10.21767/2471-853X.100036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]